ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1711

Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study

Eduardo Martin-Nares1, Oziel Amaya-Piña 2, Rosa Delia Delgado Hernández 2 and Gabriela Hernandez-Molina 1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Radiology and Molecular Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Graves' disease, IgG4 Related Disease, Imaging and diagnostic imaging, Inflammatory Eye Disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: IgG4-related ophthalmic disease (IgG4-ROD) may present as a cause of orbital myositis leading to proptosis and diplopia. This clinical scenario can be mistakenly diagnosed as Graves’ orbitopathy (GO), preventing a timely and adequately treatment. Our aim was to elucidate if there are specific radiological features that might differentiate between IgG4-ROD and GO by imaging.

Methods: We included 19 patients with diagnosis of IgG4-related disease (IgG4-RD) according to the Comprehensive Diagnostic Criteria for IgG4-RD. All had ophthalmic involvement and available computed tomography (CT) and/or magnetic resonance imaging (MRI) of the orbits. We also included 32 patients with GO with available CT and/or MRI of the orbits. Imaging studies were evaluated by a blinded head and neck radiologist for the following features: exophthalmos, extraocular muscles (EOM) size and morphology, lacrimal gland enlargement, orbital fat involvement, stretching of the optic nerve (ON), ON sheath thickening and orbital bone changes.

Results: Groups were similar in age (49.1±15.8 vs. 51.6±14.7, p=0.58) and gender (men 58.9% vs. 40.6%, p=0.23). In addition to ophthalmic involvement, 18 (94.7%) IgG4-RD patients had extra-ophthalmic involvement with a median number of organs involved of 7 (1-12). Three patients were misdiagnosed as GO before IgG4-RD diagnosis. Graves’ disease was the underlying thyroid disorder in 28 (87.5%) GO patients, Hashimoto’s thyroiditis in 2 (6.3%), papillary thyroid carcinoma in one (3.1%) and one patient was euthyroid with positive thyroid stimulating immunoglobulin. The prevalence of exophaltmos (78.9% vs. 93.8%), bilateral involvement (78.9% vs. 87.8%) and overall EOM involvement (47.4% vs. 68.8%) was similar between IgG4-ROD and GO groups. However, IgG4-ROD patients had a higher frequency of lacrimal gland involvement (73.7% vs. 10.7%, p=0.001) and a tendency for the lateral rectus to be the most frequently involved EOM (22.2% vs. 0%, p=0.07); conversely they had a lower prevalence for the inferior rectus to be the most frequently involved EOM, (33.3% vs. 72.7%, p=0.04), orbital fat involvement (47.4% vs. 81.3%, p=0.01), ON stretching (57.9% vs. 87.5%, p=0.02) and orbital bone changes (0% vs. 25%, p=0.02). EOM bellies were involved in all the IgG4-ROD and GO cases, whereas EOM tendon involvement was present in 9% of GO and in none of the IgG4-ROD group. Patients with IgG4-ROD had more frequently the combination of lacrimal gland and lateral rectus (31.6% vs. 3.1%, p=0.008) and less frequently the combination EOM and orbital fat involvement (21.2% vs. 59.4%, p=0.008).

At the logistic regression analysis we found an association of lacrimal gland involvement (OR 64.4.0, 95% CI 6.8-609.5, p=0.001) with IgG4-ROD. In a second model including combined variables, the combination of lacrimal gland and lateral rectus involvement was associated with IgG4-ROD (OR 62.5, 95% CI 3.31-1000), P=0.006), whereas the presence of EOM and orbital fat involvement was protective (OR 0.05, 95% CI 0.006-0.48, p=0.009).

Conclusion: Imaging features may reliably differentiate between IgG4-ROD and GO. The presence of both lacrimal gland and lateral rectus enlargement must alert clinicians to consider IgG4-ROD diagnosis.


Disclosure: E. Martin-Nares, None; O. Amaya-Piña, None; R. Delgado Hernández, None; G. Hernandez-Molina, None.

To cite this abstract in AMA style:

Martin-Nares E, Amaya-Piña O, Delgado Hernández R, Hernandez-Molina G. Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/distinctive-imaging-features-between-igg4-related-ophthalmic-disease-and-graves-orbitopathy-a-comparative-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinctive-imaging-features-between-igg4-related-ophthalmic-disease-and-graves-orbitopathy-a-comparative-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology